Ash Stevens: Developing Chemicals Proudly Made in the USA

Xconomy Detroit profiles Ash Stevens.

Socma Advances Sustainability Drive

Chemical Week examines SOCMA's ChemStewards® program.

Ash Stevens: Investment precedes growth investment

Ash Stevens' Dr. Stephen A. Munk, President and CEO, discusses company growth.

Ash Stevens Builds on Strengths...and Wins!

Profile of Ash Stevens. See page 28 in the Spring 2011 digital magazine. 

PharmaView: What's Your Saving Story?

Ash Stevens' Allen Brewer discusses how the company's facilities have saved on energy usage and costs by the simple act of renegotiating its gas contract.

Developing and Validating Analytical Methods for Cleaning Verification

The Ash Stevens team discusses the prevention of cross-contamination in operations where equipment is used for multiple products.

Ash Stevens Riverview Facility, USA 

Ash Stevens' Riverview, Michigan manufacturing facility is undergoing a $20m expansion to bolster production.

Big pharma more open to strong relationships, less heavy handed

Podcast: Ash Stevens' Dr. Stephen A. Munk, President & CEO, regarding big pharma's less heavy handed approach to relationships as cutbacks have made outsourcing key.

Outlook 2011

Ash Stevens’ James Hamby, Ph.D., Vice President of Business Development, shares his insights into the future direction of drug manufacturing and the supply chain.

ChemStewards® Case Study 

Ash Stevens enhances its focus on Environmental, Health, Safety and Security (EHS&S) through SOCMA’s ChemStewards® program. 

Staying On Track In The Motor City

Ash Stevens follows a path toward growth in the Detroit region.

New chemistries and facilities support large-scale pharma product manufacturing

Ash Stevens' $20 million facility expansion project will increase production by 50-80 percent and add 60 jobs to its Riverview, Michigan location.  

Communication: An Essential Element

Ash Stevens' James Hamby, R.Ph., Ph.D., Vice President of Business Development, examines the importance of communication in the Sponsor-CMO relationship. See pages 18 to 19 in the September 2010 digital magazine.

Contract Manufacturing and Continuous Flow Reactor Technology for Early-Stage Drug Development

Ash Stevens' James Hamby, R.Ph., Ph.D., Vice President of Business Development, reviews the applicability and advantages of continuous flow technology.

Pharmaceutical Company Announces $20M Expansion Project

Elected officials and SOCMA's President Larry Sloan toured the start of Ash Stevens' $20 million expansion project, which will nearly double employment and significantly increase manufacturing capacity.

Notes from the Floor at BIO 2010

Ash Stevens' multimillion dollar, multiyear expansion will add new capacity and capabilities, including new process-development laboratories, a high-potency drug development and manufacturing containment suite, a tate-of-the-art materials handling and storage facility, and a large-capacity reactor suite, among others.

SOCMA Member Ash Stevens Plans $20 Million Expansion

SOCMA reviews Ash Stevens' expansion project that will increase production by 50 to 80% and create 50 more full-time jobs.

High-Potency Expansion: Drug Compound Maker Expects Production Kick

President and CEO Stephen Munk explained how a $20 million expansion plan, which Michigan governments have supported with financial incentives, will significantly increase Ash Stevens' manufacturing capacity and employment.

Bedrock Businesses of Southwest Michigan

Ash Stevens, founded in 1962, is named as one of the bedrock businesses of the region.

People and Companies Breaking New Ground

Ash Stevens was listed as one of several biotech companies restoring Detroit's entrepreneurial edge and culture of innovation. 

Only You Can Prevent Cross-Contamination 

Ash Stevens Vice President of Quality Assurance and Regulatory Affairs Gary A. Baker, Ph.D. outlines effective cleaning procedures for CMOs.

Trends in Innovator Contract Pharmaceutical Manufacturing 

Ash Stevens Vice President of Business Development, James Hamby, Ph.D., explains how the CMO business is being impacted by the rapidly changing global pharmaceutical market.

Cleaning & Validation

Ash Stevens Vice President of Quality Assurance and Regulatory Affairs Gary A. Baker, Ph.D. outlines the solid cleaning procedures and analytical verification techniques that customers should expect of contract manufacturers.

(Video) Fine Chemicals Producer Ash Stevens: Making Quality an Issue

Alex Scott discusses Ash Stevens 50% revenue lift in 2010, expansion plans, and Silver Awards from SOCMA.

Clean and Validated

Ash Stevens outlines the solid cleaning procedures and analytical verification techniques used to prevent cross-contamination.

MEGA Board OKs Credits for 8 Projects to Bring $80 Million in Investment

The Michigan Economic Growth Authority approved a $710,019 tax credit to support Ash Steven's $14.9 million expansion and renovation project in Michigan, which Ash Stevens expects will create 60 permanent jobs.

Podcast: Lucky and Good: Sourcing Success Is in the Details

Michigan API manufacturer Ash Stevens’ emphasis on clear communication and product quality has (along with good fortune) made it a home-grown success story with an international supplier and client base. Stephen Munk, President and CEO, shares secrets of sourcing success.

Roundup of Informex 2010

Pharmaceutical Technology profiles Ash Stevens recent honor from SOCMA for achievement in environmental, health, safety, and security (EHS&S) performance.

Foreign Outsourcing of Development has Pitfalls

Ash Stevens Vice President of Business Development James Hamby, Ph.D. and Vice President of Quality Assurance Gary Baker, Ph.D. examine common pitfalls encountered when outsourcing the development and manufacture of innovator APIs and the potential hidden benefits of outsourcing locally rather than offshore.

Informex: Mixed Outlook but Optimism Prevails

Alex Scott reviews Informex-attending companies, such as Ash Stevens, with growing revenues and factories.

Cover Story: Custom Chemicals

Ash Stevens President and CEO Stephen Munk, Ph.D. discusses multi-million dollar expansion plans and domestic outsourcing trends.

Quality by Design: Adding Another Dimension to Outsourcing

Ash Stevens Vice President of Quality Assurance and Regulatory Affairs Gary A. Baker, Ph.D. explains how Ash Stevens’ approach is aligned with Quality by Design principles. 

Pharmaceutical Makers Look For Ingredients Closer To Home

Ash Stevens President and CEO Stephen Munk, Ph.D. explains reasons why it may be best to manufacture their critical ingredients closer to home, at least in the early stages of drug development.

Pharmaceutical Technology Sourcing and Management

Exhibitors announce capacity expansions, service enhancements and new products at CPhI Worldwide.

Process Development and Scale-Up for APIs

sp² profiles Ash Stevens' $6 million dollar expansion and participation and certification in SOCMA's ChemStewards program.

Pharma Not Concerned Enough about Environment when Outsourcing; CEO

CPhI coverage: Ash Stevens discusses the long-term benefits of sourcing to U.S.-based companies.

Construction Starts on New Ash Stevens Expansion Project

CPhI coverage: Ash Stevens President and CEO Stephen Munk, Ph.D. comments on project to expand API manufacturing facility.

Fast Track to Market

"Time is of the essence in getting new drugs to market, and delays in scale-up or process development mean lost sales. So when a new drug was fast-tracked by the FDA, contract manufacturer Ash Stevens had to act equally fast."

Ash Stevens Starts $6M Expansion

Ash Stevens Vice President of Business Development James Hamby, Ph.D. describes expansion plans that will bolster CMC capabilities.

Anticancer Drugs: No Option But To Outsource?

Pressures in bringing anti-cancer drugs to market may require outsourcing to companies such as Ash Stevens, according to this article.

Stateside Surge In Pharma Chemicals

Ash Stevens has invested $18.5 million since 2000 on infrastructure improvements and plans to spend another $6 million on further improvements, including a new hydrogenation cell.

Staying On Track With Fast Track

Cutting average drug approval times from more than 18 months to less than a year, Fast Track can literally be a lifesaver for a patient with a life-threatening illness.

Low Temperature Chemistry: Keep Your Cool

Industry leaders, including Ash Stevens President and CEO Stephen Munk, Ph.D., discuss low temperature chemistry technologies.

Michigan Needs A United Voice For Biotech Industry Investment

Industry leader Ash Stevens comments on Michigan biotech.

Best Practices For Cancer APIs

Interview with Ash Stevens sheds light on API development processes and the new CMC alliance.

Largest Biotech Companies

Ash Stevens ranked as the 7th largest Detroit-area biotech company by Crain's.

An Unlikely Hot Spot

Ash Stevens supports local pharmaceutical companies to revitalize the life sciences industry in Kalamazoo.

Fine Chemicals Firms Continue To Expand

Post InformEx article in Chemical & Engineering News notes Ash Stevens as a company making expansions in 2009.

InformEx Report: Contract Manufacturers Expand

InformEx post show round up highlights Ash Stevens' investments in parallel synthesis and calorimetry instrumentation and certification in SCOMA's ChemStewards program.

Ash Stevens Enhances Speed And Safety Of Scale-Up With New Investments In Parallel Synthesis And Calorimetry Instrumentation

Ash Stevens discusses new investments in parallel synthesis and calorimetry instrumentation.